Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1972 3
1973 2
1975 1
1977 1
1978 1
1990 2
1991 1
1996 1
1997 1
1998 1
2001 1
2005 2
2006 1
2007 1
2008 1
2009 2
2010 4
2011 5
2012 2
2014 2
2015 1
2016 2
2017 3
2018 3
2019 4
2020 6
2021 6
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL; UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group. Gordon KB, et al. Among authors: osuntokun oo. N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8. N Engl J Med. 2016. PMID: 27299809 Free article. Clinical Trial.
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Among authors: osuntokun oo. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
Therapeutic options for treatment-resistant depression.
Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Shelton RC, et al. Among authors: osuntokun o. CNS Drugs. 2010 Feb;24(2):131-61. doi: 10.2165/11530280-000000000-00000. CNS Drugs. 2010. PMID: 20088620 Review.
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C, Asahina A, Johnson L, Arora V, Osuntokun O, Lebwohl M. Papp K, et al. Among authors: osuntokun o. Lancet Rheumatol. 2023 Sep;5(9):e542-e552. doi: 10.1016/S2665-9913(23)00120-0. Epub 2023 Aug 21. Lancet Rheumatol. 2023. PMID: 38251498 Clinical Trial.
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A, Kimball AB, Augustin M, Okubo Y, Witte MM, Capriles CR, Sontag A, Arora V, Osuntokun O, Strober B. Blauvelt A, et al. Among authors: osuntokun o. Br J Dermatol. 2022 Dec;187(6):866-877. doi: 10.1111/bjd.21743. Epub 2022 Aug 10. Br J Dermatol. 2022. PMID: 35791755 Free PMC article. Clinical Trial.
Vertically distinct microbial communities in the Mariana and Kermadec trenches.
Peoples LM, Donaldson S, Osuntokun O, Xia Q, Nelson A, Blanton J, Allen EE, Church MJ, Bartlett DH. Peoples LM, et al. Among authors: osuntokun o. PLoS One. 2018 Apr 5;13(4):e0195102. doi: 10.1371/journal.pone.0195102. eCollection 2018. PLoS One. 2018. PMID: 29621268 Free PMC article.
58 results